Advertisement

Infection

, Volume 46, Issue 5, pp 745–747 | Cite as

Correction to: Minimum Quality Threshold in Pre-Clinical Sepsis Studies (MQTiPSS): an international expert consensus initiative for improvement of animal modeling in sepsis

  • Marcin F. Osuchowski
  • Alfred Ayala
  • Soheyl Bahrami
  • Michael Bauer
  • Mihaly Boros
  • Jean-Marc Cavaillon
  • Irshad H. Chaudry
  • Craig M. Coopersmith
  • Clifford Deutschman
  • Susanne Drechsler
  • Philip Efron
  • Claes Frostell
  • Gerhard Fritsch
  • Waldemar Gozdzik
  • Judith Hellman
  • Markus Huber-Lang
  • Shigeaki Inoue
  • Sylvia Knapp
  • Andrey V. Kozlov
  • Claude Libert
  • John C. Marshall
  • Lyle L. Moldawer
  • Peter Radermacher
  • Heinz Redl
  • Daniel G. Remick
  • Mervyn Singer
  • Christoph Thiemermann
  • Ping Wang
  • W. Joost Wiersinga
  • Xianzhong Xiao
  • Basilia Zingarelli
Open Access
Correction
  • 321 Downloads

Correction to: Infection  https://doi.org/10.1007/s15010-018-1183-8

The original version of this article unfortunately contained mistakes.

The Tables 1–3 were missing. The correct versions of Tables 1, 2 and 3 are given below.

Table 1

Combined Recommendations and Considerations from the Working Group (WG) 1 and 2

Study Design

(WG-1)

1. Survival follow-up should reasonably reflect the clinical time course of the sepsis model

R

2. Therapeutic interventions should be initiated after the septic insult replicating clinical care

3. We recommend that the treatment be randomized and blinded when feasible

4. Provide as much information as possible (e.g. ARRIVE guidelines) on the model and methodology, to enable replication.

a. Consider replication of the findings in models that include co-morbidity and/or other biological variables (i.e., age, gender, diabetes, cancer, immuno-suppression, genetic background and others).

C

b. In addition to rodents (mice and rats), consider modeling sepsis also in other (mammal) species.

c. Consider need for source control

Humane Modeling

(WG-2)

5. The development and validation of standardized criteria to monitor the well-being of septic animals is recommended

R

6. The development and validation of standardized criteria for euthanasia of septic animals is recommended (exceptions possible)

7. Analgesics recommended for surgical sepsis consistent with ethical considerations

d. Consider analgesics for nonsurgical sepsis

C

R: Recommendation strength; C: consideration strength

Table 2

Combined Recommendations and Considerations from the Working Group (WG) 3 and 4

Infection Types

(WG-3)

8. We recommend that challenge with LPS is not an appropriate model for replicating human sepsis

R

9. We recommend that microorganisms used in animal models preferentially replicate those commonly found in human sepsis

e. Consider modeling sepsis syndromes that are initiated at sites other than the peritoneal cavity (e.g. lung, urinary tract, brain)

C

Organ Failure/ Dysfunction

(WG-4)

10. Organ/system dysfunction is defined as life threatening deviation from normal for that organ/system based on objective evidence

R

11. Not all activities in an individual organ/system need to be abnormal for organ dysfunction to be present

12. To define objective evidence of the severity of organ/system dysfunction, a scoring system should be developed, validated and used, or use an existing scoring system.

13. Not all experiments must measure all parameters of organ dysfunction but animal models should be

fully exploited

f. Avoid hypoglycemia

C

R: Recommendation strength; C: consideration strength

Table 3

Combined Recommendations and Considerations from the Working Group (WG) 5 and 6

Fluid Resuscitation

(WG-5)

14. Fluid resuscitation is essential unless part of the study

R

15. Administer fluid resuscitation based on the specific requirements of the model

16. Consider the specific sepsis model for the timing of the start and continuation for fluid resuscitation

17. Resuscitation is recommended by the application of iso-osmolar crystalloid solutions

g. Consider using pre-defined endpoints for fluid resuscitation as deemed necessary

C

h. Avoid fluid overload

Anti-microbial Therapy

(WG-6)

18. Antimicrobials are recommended for pre-clinical studies assessing potential human therapeutics

R

19. Antimicrobials should be chosen based on the model and likely/known pathogen

20. Administration of antimicrobials should mimic clinical practice

i. Antimicrobials should be initiated after sepsis is established

C

R: Recommendation strength; C: consideration strength

Bettina Standhartinger was unfortunately not correctly named in the acknowledgments of the original version of this article. The correct acknowledgements are as follows:

The authors would like to thank Bettina Standhartinger for her valuable assistance in organizing the Wiggers–Bernard Conference.

The original article has been corrected.

Copyright information

© The Author(s) 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors and Affiliations

  • Marcin F. Osuchowski
    • 1
  • Alfred Ayala
    • 2
  • Soheyl Bahrami
    • 1
  • Michael Bauer
    • 3
  • Mihaly Boros
    • 4
  • Jean-Marc Cavaillon
    • 5
  • Irshad H. Chaudry
    • 6
  • Craig M. Coopersmith
    • 7
  • Clifford Deutschman
    • 8
  • Susanne Drechsler
    • 1
  • Philip Efron
    • 9
  • Claes Frostell
    • 10
  • Gerhard Fritsch
    • 11
    • 12
  • Waldemar Gozdzik
    • 13
  • Judith Hellman
    • 14
  • Markus Huber-Lang
    • 15
  • Shigeaki Inoue
    • 16
  • Sylvia Knapp
    • 17
  • Andrey V. Kozlov
    • 1
  • Claude Libert
    • 18
    • 19
  • John C. Marshall
    • 20
  • Lyle L. Moldawer
    • 9
  • Peter Radermacher
    • 21
  • Heinz Redl
    • 1
  • Daniel G. Remick
    • 22
  • Mervyn Singer
    • 23
  • Christoph Thiemermann
    • 24
  • Ping Wang
    • 25
  • W. Joost Wiersinga
    • 26
  • Xianzhong Xiao
    • 27
  • Basilia Zingarelli
    • 28
  1. 1.Ludwig Boltzmann Institute for Experimental and Clinical Traumatology in the AUVA Research CenterViennaAustria
  2. 2.Rhode Island Hospital and Alpert School of Medicine at Brown UniversityProvidenceUSA
  3. 3.Jena University HospitalJenaGermany
  4. 4.Institute of Surgical ResearchUniversity of SzegedSzegedHungary
  5. 5.Institut PasteurParisFrance
  6. 6.University of Alabama at Birmingham School of MedicineBirminghamUSA
  7. 7.Emory University School of MedicineAtlantaUSA
  8. 8.Feinstein Institute for Medical ResearchNorthwell HealthManhassetUSA
  9. 9.University of Florida College of MedicineGainesvilleUSA
  10. 10.Division of Anaesthesia and Intensive Care, Karolinska InstitutetDanderyd HospitalStockholmSweden
  11. 11.AUVA TraumacenterViennaAustria
  12. 12.Paracelsus Medical UniversitySalzburgAustria
  13. 13.Wroclaw Medical UniversityWroclawPoland
  14. 14.School of MedicineUniversity of California, San FranciscoSan FranciscoUSA
  15. 15.Institute of Clinical and Experimental Trauma-ImmunologyUniversity Hospital of UlmUlmGermany
  16. 16.Kobe University Graduate School of MedicineKobeJapan
  17. 17.Department of Medicine 1Medical University ViennaViennaAustria
  18. 18.Center for Inflammation ResearchVIBGhentBelgium
  19. 19.University GhentGhentBelgium
  20. 20.Keenan Research Centre for Biomedical Science, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  21. 21.Institute of Anaesthesiological Pathophysiology and Process DevelopmentUniversity Hospital of UlmUlmGermany
  22. 22.Boston University School of MedicineBostonUSA
  23. 23.Bloomsbury Institute of Intensive Care MedicineUniversity College LondonLondonUK
  24. 24.The William Harvey Research Institute, Barts and London School of Medicine and DentistryQueen Mary University of LondonLondonUK
  25. 25.Feinstein Institute for Medical ResearchManhassetUSA
  26. 26.Division of Infectious Diseases, and Center for Experimental and Molecular Medicine, the Academic Medical CenterUniversity of AmsterdamAmsterdamThe Netherlands
  27. 27.Xiangya School of MedicineCentral South UniversityChagnshaChina
  28. 28.Division of Critical Care Medicine, Cincinnati Children’s Hospital Medical Center, College of MedicineUniversity of CincinnatiCincinnatiUSA

Personalised recommendations